Pharming Group (NASDAQ:PHAR) Shares Gap Up – Time to Buy?

Pharming Group (NASDAQ:PHAR)’s stock price gapped up before the market opened on Tuesday . The stock had previously closed at $8.91, but opened at $9.14. Pharming Group shares last traded at $9.25, with a volume of 752 shares traded.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $37.00 price objective on shares of Pharming Group in a report on Thursday, October 10th.

Pharming Group Stock Up 0.3 %

The company has a debt-to-equity ratio of 0.40, a current ratio of 3.39 and a quick ratio of 2.65. The company has a 50-day simple moving average of $7.97 and a 200-day simple moving average of $8.58. The firm has a market cap of $602.06 million, a PE ratio of -57.88 and a beta of 0.15.

Pharming Group (NASDAQ:PHAR) last issued its earnings results on Thursday, August 1st. The company reported ($0.01) EPS for the quarter. The company had revenue of $74.09 million during the quarter, compared to the consensus estimate of $71.95 million. Pharming Group had a negative return on equity of 5.69% and a negative net margin of 4.65%. During the same quarter in the prior year, the company earned $0.02 earnings per share. Analysts expect that Pharming Group will post -0.15 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC raised its stake in Pharming Group (NASDAQ:PHAR) by 75.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 41,110 shares of the company’s stock after purchasing an additional 17,675 shares during the period. Silverberg Bernstein Capital Management LLC owned 0.06% of Pharming Group worth $339,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.